natgillin/translations-raw huggingface dataset:
The structure is identical to the human body´s own growth hormone.
Njegova zgradba je enaka zgradbi rastnega hormona v človekovem telesu.
Omnitrope 1.3 mg/ ml is for single use only.
Zdravilo Omnitrope 1, 3 mg/ ml je le za enkratno uporabo.
Omnitrope is used for
Zdravilo Omnitrope se uporablja za
• Treatment of infants, children, and adolescents:
• Zdravljenje dojenčkov, otrok in mladostnikov:
- with growth disturbance due to insufficient secretion of growth hormone (GH).
- z motnjami rasti, ki so nastale zaradi nezadostnega izločanja rastnega hormona (RH).
- with growth disturbance associated with Turner syndrome.
- z motnjami rasti, povezanimi s Turnerjevim sindromom.
- with growth disturbance associated with chronic renal insufficiency (CRI).
- z motnjami rasti, povezanimi s kronično ledvično odpovedjo (KLO).
- with growth disturbance in short children/ adolescents born small for gestational age (SGA),
- z motnjami rasti pri majhnih otrocih/ mladostnikih, ki so se za svojo gestacijsko starost rodili
who failed to show catch-up growth by 4 years of age or later.
majhni (MGS) in niso uspeli dohiteti vrstnikov pri starosti 4 leta ali več.
The
- s Prader- Willijevim sindromom (PWS), za izboljšanje rasti in sestave telesa; diagnoza PWS se
diagnosis of PWS should be confirmed by appropriate genetic testing. • Replacement of growth hormone in adults with confirmed pronounced growth hormone deficiency (GHD) originating in either childhood or adulthood.
postavi na podlagi ustreznih genetskih preiskav. • Nadomestitev rastnega hormona pri odraslih z dokazanim pomanjkanjem rastnega hormona (PRH), ki izvira bodisi iz otroštva bodisi odraslega obdobja.
BEFORE YOU USE OMNITROPE
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO OMNITROPE
Diagnosis and therapy with Omnitrope should be initiated and monitored by doctors who are appropriately qualified and experienced in the diagnosis and management of patients with growth disorders.
Diagnosticiranje in zdravljenje z zdravilom Omnitrope morajo začeti in nadzorovati zdravniki, ki so ustrezno usposobljeni in izkušeni v diagnosticiranju in zdravljenju bolnikov motnjami rasti.
- If you are allergic (hypersensitive) to somatropin or to any of the other ingredients of
- če ste alergični na (preobčutljivi za) somatropin ali katero koli drugo sestavino zdravila
Omnitrope.
Omnitrope
Anti-tumour therapy must be completed before
- če obstajajo dokazi o aktivnem tumorju: preden začnete zdravljenje, je treba zaključiti
starting therapy.
zdravljenje tumorja
- To stimulate growth if growing is already finished (closed epiphyses).
- za spodbujanje rasti, če je ta že končana (zaprte epifize)
- During acute life-threatening illness due to complications following open-heart surgery,
- med akutno smrtno nevarno boleznijo, ki je posledica zapletov po kirurškem posegu na odprtem
abdominal surgery, multiple trauma caused by an accident, acute respiratory failure, or similar conditions.
srcu, kirurškem posegu v trebuhu, večkratnih poškodbah po nesreči, akutni dihalni odpovedi ali podobnih stanjih.
Take special care with Omnitrope
Bodite posebno pozorni pri uporabi zdravila Omnitrope
- Somatropin may interfere with your body’ s use of insulin.
- Somatropin lahko vpliva na izrabo insulina v telesu.
Your blood glucose values will have
Med zdravljenjem s somatropinom se bo
to be checked regularly during therapy with somatropin.
redno nadzorovalo vaše vrednosti sladkorja v krvi.
Insulin therapy may need
- Če imate sladkorno bolezen vi ali kdo v družini: zdravljenje z insulinom bo morda treba
to be adjusted or started after somatropin therapy is initiated.
prilagoditi ali ga začeti po začetku zdravljenja s somatropinom.
- Hypothyroidism (decrease in thyroid gland function) may develop during therapy with
- Med zdravljenjem s somatropinom se lahko pojavi hipotiroidizem (zmanjšanje delovanja žleze
somatropin.
ščitnice).
Hypothyroidism may reduce the optimal response to somatropin.
Hipotiroidizem lahko zmanjša optimalni odziv na somatropin.
Therefore, thyroid hormone levels must be checked periodically during therapy.
Zato je treba občasno med zdravljenjem nadzorovati ravni ščitničnega hormona.
- Benign intracranial hypertension (high pressure within the brain) has been reported during
- Poročali so o pojavu benigne intrakranialne hipertenzije (visokem tlaku v možganih) med
treatment with somatropin.
zdravljenjem s somatropinom.
If symptoms, such as recurrent headache, visual problems, nausea, or vomiting occur, please ask your doctor for advice.
Če se pojavijo simptomi, kot so ponavljajoči se glavobol, motnje vida, slabost ali bruhanje, prosite svojega zdravnika za nasvet.
Your doctor may decide to perform an examination of the eyes to detect increased brain pressure.
Zdravnik se lahko odloči za pregled oči, da bi ugotovil zvišan tlak v možganih.
Depending on the results of this test, treatment with Omnitrope may have to be interrupted.
Glede na ugotovitve te preiskave bo morda treba zdravljenje z zdravilom Omnitrope začasno prekiniti.
- Patients with endocrine (hormonal) disorders are more likely to have problems with their hips.
Če šepate ali
If you develop a limp or pain in the hip, please ask your doctor for advice.
imate bolečine v kolkih, prosite zdravnika za nasvet.
- Progression of scoliosis (a spine curved sideways) can occur in patients who experience rapid
- Napredovanje skolioze (vstran ukrivljene hrbtenice) se lahko pojavi pri bolnikih, ki hitro
growth.
rastejo.
Therefore, signs of scoliosis should be monitored during treatment with somatropin.
Zato je treba med zdravljenjem s somatropinom spremljati znake skolioze.
However, somatropin treatment has not been shown to increase the frequency of occurrence or the severity of scoliosis.
Vendar pa za zdravljenje s somatropinom ni dokazano, da zvečuje pogostost pojavljanja ali resnost skolioze.
You will have to be examined regularly for
- Če ste imeli pred tem maligno bolezen: da bi ugotovili morebitne znake ponovitve bolezni, vas
recurrence of the malignancy.
bodo redno pregledovali.
- There is no information available on the safety of growth hormone substitution therapy in
- Podatki o varnosti nadomestnega zdravljenja z rastnim hormonom pri bolnikih z akutno kritično
patients with acute critical illness.
boleznijo niso na voljo.
If acute critical illness occurs, your doctor will have to carefully evaluate the safety of continuing somatropin treatment.
Če se pojavi akutna kritična bolezen, bo moral vaš zdravnik skrbno oceniti varnost nadaljevanja zdravljenja s somatropinom.
- Experience in patients above 60 years of age is limited.
- Izkušenj z zdravljenjem bolnikov, starih več kot 60 let, je malo.
Patients with chronic renal insufficiency (CRI)
Bolniki s kronično ledvično odpovedjo (KLO)
- In patients with CRI, somatropin therapy should not be started unless the function of the kidney
- Bolnike s kronično ledvično odpovedjo se s somatropinom lahko zdravi le, če delovanje ledvic
is below 50 percent of normal.
znaša manj kot 50 odstotkov normalnega delovanja.
To verify growth disturbance, growth should be followed for one year before starting therapy.
Motnje rasti se preverja tako, da se rast spremlja eno leto pred začetkom zdravljenja.
Conservative treatment for CRI should be continued during treatment with somatropin.
Konzervativno zdravljenje kronične ledvične odpovedi se naj nadaljuje med zdravljenjem s somatropinom.
After kidney transplantation, treatment with somatropin should be stopped.
Po presaditvi ledvic je treba zdravljenje s somatropinom ustaviti.
Patients with Prader-Willi syndrome (PWS)
Bolniki s Prader- Willijevim sindromom (PWS)
- In patients with PWS, treatment with somatropin should always be combined with a calorie-
- Pri bolnikih s PWS je treba zdravljenje s somatropinom vedno dopolniti s prehrano z manjšim
restricted diet.
vnosom kalorij.
- Experience with prolonged treatment in patients with PWS is limited.
- Izkušenj z dolgotrajnim zdravljenjem bolnikov s PWS je malo.
- There have been reports of deaths associated with the use of growth hormone in patients with
- Poročali so o smrtnih primerih, povezanih z uporabo rastnega hormona pri bolnikih s PWS, ki
PWS who had one or more of the following risk factors: severe obesity, history of severe breathing problems, especially during sleep, or infection of the lungs or airways.
so imeli enega ali več od naslednjih dejavnikov tveganja: čezmerno debelost, hude težave z dihanjem v preteklosti, posebno med spanjem, ali okužbo pljuč ali dihal.
Before starting on Omnitrope, you should be checked for breathing problems and respiratory infections by a doctor, even if you have not been experiencing any symptoms of breathing difficulty.
Pred začetkom zdravljenja z zdravilom Omnitrope vas mora zdravnik pregledati zaradi možnosti težav z dihanjem in okužb dihal, četudi niste imeli nobenih simptomov oteženega dihanja.
- If any infection of your lungs or airways is found, you must be treated sufficiently before
- Če se ugotovi, da imate katero koli okužbo pljuč ali dihal, se morate pred začetkom zdravljenja
starting treatment with somatropin.
s somatropinom dovolj pozdraviti.
You should be monitored for signs of infection while being treated with somatropin.
Med zdravljenjem s somatropinom vas bo treba zaradi morebitnega pojava znakov okužbe spremljati.
- Difficulty breathing while asleep, called sleep apnoea, should be examined by a specialist.
- V primeru oteženega dihanja med spanjem, imenovanega apneja, vas mora pregledati specialist.
Before initiation of growth hormone therapy, you should be observed for breathing problems during the night using a special monitor.
Pred začetkom zdravljenja z rastnim hormonom, vas mora glede oteženega dihanja ponoči prek posebnega zaslona opazovati zdravnik.
If any problems are found, then you should continue to be monitored during sleep.
Če ugotovi kakršnekoli težave, vas mora še naprej opazovati med spanjem.
- If during treatment with somatropin you show signs of breathing problems (onset or increase of
- Če imate med zdravljenjem s somatropinom težave z dihanjem (če ste začeli smrčati ali smrčite
snoring), treatment should be interrupted and the cause should be examined by a doctor.
močneje), je treba zdravljenje začasno prekiniti, zdravnik pa mora raziskati vzrok težav.
- All patients with PWS should have effective weight control before and during treatment with
- Pri vseh bolnikih s PWS je treba učinkovito nadzorovati telesno težo pred začetkom zdravljenja
somatropin.
s somatropinom in med njim.
Patients born SGA
59 Bolniki, ki se rodijo majhni za svojo gestacijsko starost
- In patients born SGA, other medical reasons or treatments that could explain the growth
- Pri bolnikih, ki se rodijo majhni za svojo gestacijsko starost, je treba izključiti druge
disturbance should be ruled out.
zdravstvene razloge ali zdravljenje, ki bi lahko pojasnili motnjo rasti.
Therefore,
- Izkušenj z začetkom zdravljenja pri bolnikih, MGS, pri katerih se bo kmalu začela puberteta, je
treatment should not be started near the onset of puberty.
Zato se ne priporoča začetek zdravljenja tik pred začetkom pubertete.
- Experience in patients with Silver-Russell syndrome is limited.
- Izkušenj pri bolnikih s Silver- Russellovim sindromom je malo.
- Some of the height gain obtained with treating short children/ adolescents born SGA with
- Nekaj pridobljenih centimetrov telesne višine pri otrocih/ mladostnikih, ki so se rodili majhni za
somatropin may be lost if treatment is stopped before final height is reached.
svojo gestacijsko starost, s pomočjo zdravljenja s somatropinom, se lahko izgubi, če zdravljenje ustavimo, preden se doseže končna telesna višina.
- Blood sugar and insulin levels should be checked before the start of treatment and annually
- Pred začetkom zdravljenja in nato enkrat na leto ves čas zdravljenja z rastnim hormonom je
during treatment with growth hormone.
treba preverjati vrednost sladkorja v krvi in insulina.
- Please tell your doctor or pharmacist if you are taking or have recently taken any other
- Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli
medicines, including medicines obtained without a prescription.
zdravilo, tudi če ste ga dobili brez recepta.
It is especially important to tell your doctor if you are taking any medicine for diabetes, thyroid disorder or any anticonvulsants, ciclosporin or steroid hormones such as oestrogens, progesterone or corticosteroids.
Zelo pomembno je, da zdravniku poveste, če jemljete kakršna koli zdravila za sladkorno bolezen, motnje ščitnice, zdravila proti epilepsiji, ciklosporin ali steroidne hormone, kot so estrogeni, progesteron ali kortikosteroidi.
A dose adjustment may be needed for these medicines.
Za ta zdravila bo morda potrebno prilagoditi odmerek.
Treatment with Omnitrope should be interrupted during pregnancy.
Zdravljenje z zdravilom Omnitrope je treba med nosečnostjo prekiniti.
Ask your doctor for advice before using Omnitrope if you are breast-feeding.
Če dojite, se pred uporabo zdravila Omnitrope posvetujte z zdravnikom.
HOW TO USE OMNITROPE
KAKO UPORABLJATI ZDRAVILO OMNITROPE
This means that it is injected through a short injection needle into the fatty tissue just under your skin.
To pomeni, da se injicira s pomočjo kratke injekcijske igle v maščevje tik pod kožo.
You will receive appropriate training and instruction on the proper use of Omnitrope from your doctor or other suitably qualified health professional.
Vaš zdravnik ali drugo primerno usposobljeno zdravstveno osebje vas bo ustrezno usposobilo in dalo navodila o pravilni uporabi zdravila Omnitrope.
For instructions on how to inject Omnitrope, see section “ How to inject Omnitrope” below.
Navodila o tem, kako injicirati zdravilo Omnitrope, so v nadaljevanju v poglavju » Kako injicirati zdravilo Omnitrope «.
Treatment with somatropin is a long-term treatment.
Zdravljenje s somatropinom je dolgotrajno.
If you want to know more about what that means for you, please ask your doctor.
Če želite izvedeti več o tem, kaj to za vas pomeni, vprašajte svojega zdravnika.
How much and how often to use Omnitrope
Koliko zdravila Omnitrope uporabiti in kako pogosto
Your doctor will advise you about your individualised dose of Omnitrope and treatment schedule.
Zdravnik vam bo svetoval glede posameznih odmerkov zdravila Omnitrope v vašem načrtu zdravljenja.
Usually Omnitrope is injected once a day in the evening.
Ponavadi se zdravilo Omnitrope injicira enkrat na dan, in sicer zvečer.
Please do not change the dosage and treatment schedule without consulting your doctor.
Prosimo, da ne spreminjate načrta odmerjanja in zdravljenja, ne da bi se prej posvetovali z zdravnikom.
Dose adjustments may be required over time, depending on your increase in body weight and response.
Sčasoma bo morda potrebna prilagoditev odmerkov, kar je odvisno od zvečanja telesne mase in odziva.
61 If you use more Omnitrope than you should
60 Če ste uporabili večji odmerek zdravila Omnitrope, kot bi smeli
Acute overdose may lead initially to hypoglycaemia (decrease in blood glucose) and subsequently to hyperglycaemia (increase in blood glucose).
Akutni preveliki odmerki lahko na začetku povzročijo hipoglikemijo (zmanjšanje vrednosti sladkorja v krvi) in pozneje hiperglikemijo (zvečanje vrednosti sladkorja v krvi).
Long-term overdosage could result in signs and symptoms of gigantism or acromegaly (enhanced growth of ears, nose, lips, tongue, and cheekbones).
Dolgotrajni preveliki odmerki lahko povzročijo znake in simptome čezmerne rasti (gigantizma) ali akromegalije (pospešene rasti ušes, nosu, ustnic, jezika in ličnih kosti).
If you have used more Omnitrope than you should, please ask your doctor for advice.
Če ste vzeli večji odmerek zdravila Omnitrope, kot bi smeli, prosite zdravnika za nasvet.
If you forget to take Omnitrope
Če ste pozabili vzeti zdravilo Omnitrope
Do not inject a double dose to make up for forgotten individual doses.
Ne injicirajte si dvojnega odmerka, če ste pozabili vzeti prejšnjega.
Continue with the prescribed dosage regimen.
Nadaljujte tako, kot vam je bilo predpisano.
If you forget to take Omnitrope, please ask your doctor for advice.
Če ste pozabili vzeti zdravilo Omnitrope, prosite zdravnika za nasvet.
How to inject Omnitrope 1.3 mg/ ml
Kako si je treba injicirati zdravilo Omnitrope 1, 3 mg/ ml
The following instructions explain how to inject Omnitrope 1.3 mg/ ml yourself.
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope, 1, 3 mg/ ml.
Your doctor or other suitably qualified health professional will show you how to inject Omnitrope.
Zdravnik ali drugo ustrezno usposobljeno zdravstveno osebje vam bo pokazalo, kako si injicirati zdravilo Omnitrope.
Do not attempt to inject unless you are sure you understand the procedure and requirements for injection.
Ne poskušajte si ga injicirati, če niste prepričani, da razumete postopek in zahteve glede injiciranja.
- Change the injection sites to minimise the risk of local lipoatrophy (local reduction of fatty
- Spreminjajte mesta injiciranja, da boste tako čim bolj zmanjšali nevarnost lokalne lipoatrofije
tissue under the skin).
(lokalnega zmanjšanja maščobnega tkiva pod kožo).
Preparation Collect necessary items before you begin:
Priprava Preden začnete, si pripravite vse potrebno:
- a vial with Omnitrope 1.3 mg/ ml powder for solution for injection.
- vialo s praškom za raztopino za injiciranje zdravila Omnitrope
- a vial with solvent for Omnitrope 1.3 mg/ ml.
- vialo z vehiklom Omnitrope 1, 3 mg/ ml
- a sterile, disposable syringe (e. g.
- sterilno injekcijsko brizgo (npr.
2 ml syringe) and needle (e. g.
2- mililitrsko) in iglo (npr.
0.33 mm x 12.7 mm) for withdrawing the solvent from the vial (not supplied in the pack).
x 12, 7 mm) za odstranitev topila iz viale (ki je ni v ovojnini)
- a sterile, disposable syringe of appropriate size (e. g.
- sterilno injekcijsko brizgo za enkratno uporabo primerne velikosti
1 ml syringe)
(npr.
and injection needle (e. g.
1- mililitrsko) in injekcijsko iglo (npr.
0.25 mm x 8 mm) for subcutaneous injection (not supplied in the pack).
0, 25 mm x 8 mm) za subkutano injiciranje (ki je ni v ovojnini)
- 2 cleansing swabs (not supplied in the pack).
- 2 blazinici iz vate za čiščenje (ki ju ni v ovojnini).
- Remove the protective caps from the two vials in the box.
- Odstranite zaščitni zaporki z obeh vial v škatlici.
With a
Z blazinico iz vate
cleansing swab, disinfect the rubber membranes of both the powder-filled and the solvent-filled vial.
razkužite gumijasto membrano viale, napolnjene s praškom, in viale, napolnjene z vehiklom.
- Take the vial with solvent and the sterile, disposable syringe (e. g.
- Vzemite vialo z vehiklom in sterilno injekcijsko brizgo za enkratno
2 ml syringe) and needle (e. g.
2- mililitrsko) ter iglo (npr.
solvent from the vial.
- Viale z vehiklom obrnite navzdol in iz nje izčrpajte vse topilo.
- Take the vial with the powder and push the needle through the
- Vzemite vialo s praškom in potisnite iglo skozi gumijasto
rubber membrane of the vial.
membrano.
- Gently swirl the reconstituted vial until the content is completely
- Vialo s pripravljeno raztopino narahlo vrtite, dokler se vsebina
dissolved.
povsem ne raztopi.
- If the solution is cloudy (and the cloudiness does not disappear
- Če je raztopina motna (in motnost ne izgine v 10 minutah) ali
within ten minutes) or contains particles, it should not be used.
vsebuje delce, je ne smete uporabiti.
1 ml
- Vzemite sterilno brizgo primerne velikosti za enkratno uporabo
syringe) and injection needle (e. g.
1- mililitrsko) in injekcijsko iglo (npr.
- Push the needle through the rubber stopper of the vial with the
- Iglo potisnite skozi gumijast zamašek v viali s pripravljeno
reconstituted solution.
raztopino.
- Turn the vial and the syringe upside down in one hand.
- Z eno roko obrnite vialo in injekcijsko brizgo navzdol tako, da
- Be sure that the tip of the syringe is in the Omnitrope reconstituted
- Prepričajte se, da je konica injekcijske brizge v pripravljeni
solution.
raztopini zdravila Omnitrope.
- Pull back on the plunger slowly and withdraw just a bit more than
- Počasi potiskajte bat nazaj in načrpajte v brizgo le nekoliko večjo
the dose prescribed by your doctor into the syringe.
količino, kot je odmerek, ki vam ga je predpisal zdravnik.
- Hold the syringe with the needle in the vial pointing up and remove
- Brizgo z iglo držite v viali s konico navzgor in jo potegnite iz viale.
the syringe from the vial.
- Preverite, da v brizgi ni zračnih mehurčkov.
If you see any bubbles, pull
Če jih opazite, bat
the plunger slightly back; tap the syringe gently, with the needle pointing upwards, until the bubbles disappear.
narahlo povlecite nazaj; injekcijsko brizgo narahlo potolcite, pri tem pa naj bo igla obrnjena navzgor, dokler mehurčki ne izginejo.
- Inspect the reconstituted solution visually prior to administration.
- Pred uporabo preglejte pripravljeno raztopino.
The best sites for injection are tissues
Najprimernejša mesta za injiciranje so
with a layer of fat between skin and muscle, such as the thigh or belly (except the navel or waistline).
tkiva s plastjo maščobe med kožo in mišicami, npr. stegno ali trebuh (razen popka ali pasu).
- Make sure you inject at least 1 cm from your last injection site and
- Bodite pozorni, da si zdravilo injicirate najmanj 1 cm stran od
that you change the places where you inject, as you have been taught.
mesta zadnjega injiciranja in da zamenjate mesto injiciranja, kot so vas naučili.
- Before you make an injection, clean your skin well with an alcohol
- Pred injiciranjem dobro očistite kožo z blazinico iz vate, namočeno
swab.
v alkohol.
With your other hand,
Z drugo roko držite brizgo, kot bi
hold the syringe as you would a pencil.
držali svinčnik.
- After injection, press the injection site with a small bandage or
- Po injiciranju pritiskajte na mesto injiciranja več sekund z majhnim
sterile gauze for several seconds.
povojem ali sterilno gazo.
- The residual solution, vials, and injection materials intended for
- Ostanke raztopine, vial in pribor za injiciranje, namenjen enkratni
single use must be discarded.
62 uporabi, morate zavreči.
63 If you stop using Omnitrope
Če ste prenehali uporabljati zdravilo Omnitrope
A disruption or early ending of treatment with somatropin may impair the success of growth hormone therapy.
Začasna ustavitev ali zgodnji konec zdravljenja s somatropinom lahko vpliva na uspešnost zdravljenja z rastnim hormonom.
Please ask your doctor for advice before stopping treatment.
Preden prenehate zdravljenje, prosite zdravnika za nasvet.
Like all medicines, Omnitrope can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Omnitrope neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Please ask your doctor for advice when you experience any of the symptoms described below.
Posvetujte s svojim zdravnikom, kadar imate katerega od spodaj naštetih simptomov.
General disorders and reactions at the injection site
pogosto (pojavljajo se pri vsaj 1 bolniku od 100, vendar manj kot pri 1 od 10)
Common (occurring in at least 1 of 100 but less than 1 of 10 patients) In infants/ children/ adolescents: transient local skin reactions
občasno (pojavljajo se pri vsaj 1 bolniku od 1. 000, vendar manj kot pri 1 od 100) pri
Uncommon (occurring in at least 1 of 1,000 but less than 1 of 100 patients) In infants/ children/ adolescents: mild oedema
redko (pojavljajo se pri vsaj 1 bolniku od 10. 000, vendar manj kot pri 1 od 1. 000)
Rare (occurring in at least 1 of 10,000 but less than 1 of 1,000 patients)
zelo redko (pojavljajo se pri manj kot 1 bolniku od 10. 000)
Very Rare (occurring in less than 1 of 10,000 patients)
mladostnikih: prehodne lokalne reakcije na koži
In adults: mild oedema
pri odraslih:
Musculoskeletal system, connective tissues, bones
dojenčkih/ otrocih /
In adults: stiffness of the limbs, joint and muscle pain
okorelost okončin,
In infants/ children/ adolescents: stiffness of the limbs, joint and muscle pain
okorelost okončin,
Nervous system
benigna živčevje
In adults: sensory disturbances
pri odraslih: motnje pri
In infants/ children/ adolescents: sensory disturbances
pri dojenčkih/ otrocih /
Benign intracranial hypertension
intrakranialna hipertenzija